Neil McFarlane
Directeur Général chez ZEVRA THERAPEUTICS, INC.
Fortune : 2 M $ au 30/04/2024
Postes actifs de Neil McFarlane
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Directeur/Membre du Conseil | 06/04/2022 | - |
| Independent Dir/Board Member | 06/04/2022 | - | |
| ZEVRA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 10/10/2023 | - |
| Directeur Général | 10/10/2023 | - | |
| President | 10/10/2023 | - |
Historique de carrière de Neil McFarlane
Anciens postes connus de Neil McFarlane
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Adamas Pharmaceuticals, Inc. | Directeur/Membre du Conseil | 01/09/2019 | 01/11/2021 |
| Directeur Général | 01/09/2019 | 01/11/2021 | |
| ADAMAS PHARMACEUTICALS, INC. | Directeur Général | 16/09/2019 | 01/01/2021 |
| TRAVERE THERAPEUTICS, INC. | Directeur des opérations | 15/08/2016 | 31/05/2019 |
UCB, Inc.
 UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Corporate Officer/Principal | 01/01/2011 | 01/01/2016 |
Formation de Neil McFarlane
| University of Florida | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 8 |
Opérationnelle
| Chief Executive Officer | 3 |
| Director/Board Member | 3 |
| Chief Operating Officer | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 2 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
| ZEVRA THERAPEUTICS, INC. | Health Technology |
| TRAVERE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Finance |
| Adamas Pharmaceuticals, Inc. |
- Bourse
- Insiders
- Neil McFarlane
- Expérience